RhoVac Reports to Mount Sinai Hospital in New York Join Phase IIb Study in Prostate Cancer
The participation of Mount Sinai was directly caused by the FDA approval of RhoVac's Fast Track Designation.
The participation of Mount Sinai was directly caused by the FDA approval of RhoVac's Fast Track Designation.